In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Akrimax Pharmaceuticals, LLC

Latest From Akrimax Pharmaceuticals, LLC

FDA Lull In Rx Promotion Citations Continues; Guidances May Be Bigger Priority

Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.

BioPharmaceutical Regulation

FDA Suppresses Suprenza Site, But Coupon Link Remains

FDA sends untitled letter to Citius Pharmaceuticals and licensee Akrimax for not including any risk information on webpage for weight loss product; Akrimax received a similar citation in March for a Tirosint Facebook page.

BioPharmaceutical United States

Facebook Page Cannot Leave Out Risk Information, FDA Says

Office of Prescription Drug Promotion also expresses concern that Facebook page for hypothyroidism drug Tirosint fails to include limits on the indication.

BioPharmaceutical United States

IN VIVO: Deals Shaping The Medical Industry, May 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals